Is CBD the missing link in IBS treatment?

In this episode, I’m joined by Dr. Chris Schneider and Rick Palesh — the minds behind SVG and the Genesis Study, a first-of-its-kind clinical trial investigating CBD’s potential to relieve pain caused by Irritable Bowel Syndrome. The study is currently under review and expected to be published in the coming months and the results could be a game-changer.

We dig into the science, the unexpected findings (including a wild placebo effect), and what it really takes to push cannabis research forward in a clinical setting. From dosing dilemmas to regulatory hurdles, this is a rare behind-the-scenes look at the future of cannabinoid medicine and gut health.

🎧 Whether you’re a patient looking for answers, a practitioner hungry for data, or just curious about the next frontier of cannabis research — this one’s for you.

👉 Got a Rapid Fire question you want me to ask a guest? Email me at [email protected] — I love including questions from the community.

💚 Like what I’m doing? You can support the podcast at buymeacoffee.com/auscannapodcast — every bit helps keep these conversations going!

In this episode, we cover a lot of topics, including:

* Rapid Fire (2:23)

* Who are Dr. Chris Schneider and Rick Palesh? (19:13)

* What is the Genesis study? (22:12)

* Placebo Effect… It’s crazy strong! (23:56)

* How did the Genesis study approach dosing? (30:10)

* What were some of the biggest hurdles the Genesis study faced? (31:09)

* Were there any regulatory roadblocks in conducting the clinical trial? (33:08)

* Cannabinoid research is still evolving, was it difficult to get approval or funding? (34:19)

* The challenges of translating research findings into real-world treatment options (35:21)

* Will these results open the door to further research on CBD and gut health? (36:23)

* Specific aspects of CBD’s effects on IBS that Dr. Schneider and Rick would like to investigate next (38:18)

* Potential plans to expand research into other cannabinoids, such as CBG or CBN (40:14)

* In an ideal world with unlimited resources, what would the next phase of SVG’s research look like? (42:33)

* Advice for patients trying to navigate CBD on their own (45:17)

* The edibles tangent (49:33)

* The most underrated cannabinoid in terms of therapeutic potential (57:45)

* The importance of paitent reported data (59:36)

* Dr. Schneider and Rick’s call to action (61:39)

Show Notes:

Where to Find Dr. Chris Schneider and Rick Palesh:

* SVG Website

* Email [email protected]

Where to find me:

* @AusCannaReviews on SubStack

* @AusCannaReviews on Instagram

* @AusCannaReviews on Twitter/X

* Email [email protected]

* Buy Me A Coffee/AusCannaPodcast

This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit auscannareviews.substack.com